iPSC colony.png

UNDERSTANDING

STEM CELL THERAPIES:

Separating HOPE from HYPE

December 9, 2020  |  Time: 3:00pm-5:00pm PST

WEDNESDAY, DECEMBER 09, 2020

UNDERSTANDING STEM CELL THERAPIES: 

SEPARATING HOPE & HYPE

Helping your patients navigate regenerative medicine.

Featured Guest Speakers: 

    Zubin Master, Ph.D.

    Jane Lebkowski, Ph.D.

    Paul Knoepfler, Ph.D.

Wednesday, December 9, 2020

Time: 3:00pm-5:00pm PST

Special Guest Moderator:

Beth Roxland, J.D., M. Bioethics

Founder and Strategic Advisor, Roxland Consultants Ltd.

Registration: OPEN NOW

Cost:  $35.00

MDs, PAs & RNs: This course offers 2 CME credits. These credits are Category-1 CME credits.

Sponsored by, The Seim Family and funded, in part,

by a grant from the San Diego County Board of Supervisors.

DESCRIPTION

Format:

A live webinar with 

moderated presentations from our featured guest speakers, followed by a Q&A discussion.

What is regenerative medicine?   

 

 What - exactly - are stem cells?   

 

Do stem cell therapies work?

Information from renowned experts about:

      Stem Cells  |  Stem Cell Therapies     

 Evidence-based Research & Clinical Trials 

  Stem Cell Tourism

Enabling you to help your patients safely separate HOPE from HYPE

Helping patients navigate regenerative medicine.

There is a great interest in regenerative medicine as an alternative treatment for those with unmet medical needs. Renowned speakers will provide evidence-based information about

  • the capabilities of stem cells.

  • pursuing regenerative medicine therapy options

  • navigating regenerative medicine by improving communication & understanding.

Elevate you understanding of regenerative medicine and enhance your ability to separate HOPE from HYPE. 

IN ORDER OF APPEARANCE:

Beth Roxland, J.D., M. Bioethics

Founder and Strategic Advisor, Roxland Consultants Ltd.

Special Guest Moderator

 

Beth E. Roxland is an Attorney and Bioethicist with unique experience across industry, law, government and academia. She is the Founder of Roxland Consultants Ltd., and serves as an independent advisor to law firms, academic medical centers, life-science and research entities, providing strategic support and guidance on complex regulatory, ethical, operational and communications challenges. Beth also serves on several oversight boards, and is a frequent author and public speaker.

Ms. Roxland was previously the Bioethics & Strategy Leader for Johnson & Johnson in its Chief Medical Office (Global).  In this industry-leading position, she launched an enterprise-wide Research Ethics Consultation Service to provide teams and individuals with real-time support on complex ethical R&D issues, and led the first-of-its-kind major colloquium partnering to foster public dialog and potential policy-making between industry, academia, non-profits and governmental entities on challenging ethical issues surrounding Early Access to experimental interventions. She also advised on commercialization of stem cell therapies, conducting clinical trials in war-torn regions, testing of a potential Ebola vaccine during a public health crisis, subject recruitment and withdrawal, and Expanded Access/ Compassionate Use and Right to Try, and research involving children and other “vulnerable populations.”

Prior to joining J&J, Ms. Roxland was the Executive Director of the New York State Task Force on Life and the Law (the State’s Bioethics Commission), where she led comprehensive reports – which were later adopted by the State into law, regulation and guidance – on the Allocation of Ventilators in a Pandemic Influenza, Determination of Brain Death, and Research with Adults Lacking Full Consent Capacity. While with the State, she concurrently served as the Special Advisor to the Commissioner of Health on Stem Cell Research Ethics, where she drove thoughtful policy for novel, sensitive types of stem cell research, including on SCNT, usage of embryos in research, and payment for gamete donation.

Beth began her career as an attorney, where she was a Senior Associate in the litigation department of Simpson Thacher and Bartlett LLP, and as a Federal Law Clerk in the Southern District of New York (S.D.N.Y.).

She graduated from Columbia University with a Bachelor’s degree in biology, and received a joint J.D.- Master’s in Bioethics mage cum laude from the University of Pennsylvania.

Jeanne Loring, Ph.D.

Director & Chief Science Officer, Summit for Stem Cell Foundation.

Professor, Scripps Research Institute

Founder, Aspen Neuroscience

Honored Speaker

Jeanne F. Loring is the Professor Emeritus at the Scripps Research Institute where she was founding Director of the Center for Regenerative Medicine. She is also founder of two stem cell-based biotechnology companies, Arcos Bioscience (now part of Viacyte) and Aspen Neuroscience, a biotechnology company developing a neuron replacement therapy for Parkinson disease.  Dr. Loring has more than 30 years of experience in both biotechnology and academic research, focusing on stem cells, genomics, embryology and neurobiology. She holds five patents on stem cells and genomics, and has published more than 100 research articles in scientific journals that have been cited in scientific publications more than 14,000 times. She serves on both scientific advisory and bioethics boards, and advises governmental and private granting agencies in several countries. Through her laboratory courses, she has trained more than 400 scientists in stem cell technology.

In addition to her work on Parkinson disease, Dr. Loring investigates multiple sclerosis and autism, and works with the San Diego Zoo Institute for Conservation Research in an effort to rescue the Northern white rhinoceros from extinction using stem cell technology.  She is also involved in a project on the International Space Station to study neurogenerative disease.

Dr. Loring is an advocate for patients and an outspoken critic of stem cell clinics that operate outside of ethical or scientific oversight. She speaks out against unregulated stem cell therapies that have  caused severe injuries and even death, and the clinics who convince desperately ill patients to pay for treatments that are not effective

Zubin Master, Ph.D.

Associate Professor of Biomedical Ethics, Biomedical Ethics Research Program and Center for Regenerative Medicine, Mayo Clinic, Rochester Minnesota

Featured Guest Speaker

The research interests of Zubin Master, Ph.D., broadly cover ethical and policy issues related to regenerative medicine and stem cell research, genetics, research ethics, and the responsible conduct of research. More specifically, Dr. Master's interests rest on understanding how personal beliefs, information, and perceptions of scientific evidence impact health care decision-making. Dr. Master's work centers on the translation and commercialization of stem cell interventions and the direct-to-consumer market of FDA-unapproved stem cell treatments. He is also interested in ethical and policy issues related to Right to Try and the FDA's Expanded Access Program.

Jane S. Lebkowski, Ph.D.

President, Regenerative Patch Technologies (RPT)

Featured Guest Speaker

 

Jane Lebkowski has been actively involved in the development of cell and gene therapies since 1986 and is President of Regenerative Patch Technologies (RPT), a biotechnology firm developing composite stem cell-based implants targeting restoration of retinal architecture and function in patients with macular degeneration. In this role, Dr Lebkowski oversees all of RPT’s operations.

 

From 2013-2017, Jane Lebkowski also served as Chief Scientific Officer and President of R&D at Asterias Biotherapeutics Inc, where she headed all preclinical, product, regulatory, and clinical development of Asterias’ regenerative medicine and dendritic cell based-cancer immunotherapy products.    Prior to joining Asterias, Dr. Lebkowski was Senior Vice President of Regenerative Medicine and Chief Scientific Officer at Geron Corporation.  Dr. Lebkowski led Geron’s human embryonic stem cell program from 1998-2012 and was responsible for all research, preclinical development, product development, manufacturing, and clinical development activities supporting cell-based therapies for several regenerative medicine indications including spinal cord injury and cardiovascular disease.  From 1986-1998, Dr. Lebkowski was Vice President of Research and Development at Applied Immune Sciences where she directed activities to develop T cell based cancer immunotherapies for solid tumors, hematologic malignancies and AIDs.  Following the acquisition of Applied Immune Sciences by Rhone Poulenc Rorer (RPR, currently Sanofi), Dr. Lebkowski remained at RPR as Vice President of Discovery Research.  During Dr. Lebkowski’s tenure at RPR, she coordinated preclinical investigations of gene therapy approaches for treatment of cancer, cardiovascular disease and nervous system disorders, and directed vector formulations and delivery development.  Dr. Lebkowski received her Ph.D. in Biochemistry from Princeton University in 1982, and completed a postdoctoral fellowship at the Department of Genetics, Stanford University in 1986.

 

Dr. Lebkowski has published over 80 peer reviewed publication and has 13 issued U.S. patents.  Dr. Lebkowski has served on the board of Directors of the American Society for Gene and Cell Therapy and on numerous scientific advisory boards and professional committees including those supported by ASGCT and ISSCR.

Paul Knoeplfer, Ph.D.

Professor, Department of Cell Biology and Human Anatomy, the Genome Center, and the Comprehensive Cancer Center at the University of California, Davis School of Medicine.

Featured Guest Speaker

The Knoepfler Lab is interested in epigenetics in stem cells and cancer. We use cutting edge molecular, cellular and developmental biology methods as well as genomic and gene editing technologies to answer key open questions in these areas of research. We are particularly interested now in the roles of three factors normally in stem cells and during tumorigenesis: histone variant H3.3, the MYC family, and DPPA4. How do these factors link the epigenome to cellular behaviors and tissue growth?

Knoepfler was diagnosed with prostate cancer in late 2009 at age 42, an experience he credits at least in part as the inspiration to start blogging as an academic stem cell researcher. As of 2012, Knoepfler was the only stem cell scientist in the United States who regularly blogged about stem cells. Knoepfler remains in long-term remission from prostate cancer after surgery in 2009. In addition to blogging about stem cells, he blogged about his experience with prostate cancer, a disease that is often not discussed openly by men.

Knoepfler received tenure in 2011 while actively blogging, an event he claims demonstrates a growing acceptance of social media in academia. He is a proponent of scientific social media and has been listed as the top person to follow on Twitter to stay current on events in the stem cell field. His blog at http://www.ipscell.com has broken a number of stem cell news stories, including the fraud of Hisashi Moriguchi of Japan, who claimed to have transplanted iPS cells into humans as early as 2012; the unawarded third position for the 2012 Nobel Prize in Physiology or Medicine; and the explosion of stem cell cosmetics. In addition to his blogging, in 2013 Knoepfler released a book titled Stem Cells: An Insider's Guide, which is aimed at a general audience of both scientists and non-scientists.[28]

As part of education and advocacy efforts, Knoepfler has supplied his own funds to support advancing the stem cell cause. In 2012, he awarded multiple $50 iTunes gift cards as prizes for a stem cell essay contest and started a Stem Cell Person of the Year Award that includes a $1,000 cash prize given from Knoepfler's own money. The first winner of this award was stem cell and spinal cord injury patient advocate, Roman Reed.

In 2015, Knoepfler published a new book, titled GMO Sapiens: The Life-Changing Science of Designer Babies, which discusses the science of human genetic modification. His second book covers the new CRISPR gene editing technology and its possible use in humans, cloningeugenics, and transhumanism. Knoepfler advocates in the book for a temporary moratorium on clinical use of CRISPR in humans, whether for health condition or even human enhancement to create designer babies. In a TEDx Vienna talk titled "What if my neighbor's kid was genetically modified?" he addresses his concerns on the use of CRISPR in humans.

Rita Ceponiene, M.D., Ph.D.

American Board of Psychiatry and Neurology certified member of the American Academy of Neurology and the Movement Disorders Society

Director and Medical Advisor, Summit for Stem Cell Foundation

Panelist

Dr. Ceponiene is American Board of Psychiatry and Neurology certified member of the American Academy of Neurology and the Movement Disorders Society, with a PhD in Cognitive Neuroscience at the Helsinki University, Finland. She has published over 40 peer – reviewed research articles during her academic career. Dr. Ceponiene has since returned to clinical work currently is a movement disorders specialist at Southern California Kaiser Permanente, San Diego. She continues to maintain ties with her academic colleagues and is passionate about educating patients and health care providers about the developments in the field. One of them is the promise of the autologous dopamine neuron replacement therapy that is being developed within a rigorous scientific framework.

Abigail Lawler, M.D. 

Panelist

Director/Medical Advisor, Summit for Stem Cell Foundation

Dr. Lawler is a board-certified member of the American Board of Psychiatry and Neurology and is a member of the American Academy of Neurology and the Movement Disorders Society. Dr. Lawler is originally from Ohio where she completed undergrad at Ohio University and also studied abroad through Duke University in Costa Rica where she completed a Spanish immersion program. She came back to Ohio for medical school at University of Toledo and then went on to complete her residency training in neurology at Medstar Georgetown University Hospital in Washington D.C., where she served as chief resident. Dr. Lawler stayed at Georgetown University to complete a fellowship in Movement and Memory Disorders at the highly acclaimed Translational Neurotherapeutics Program where she was extensively involved in clinical research, including the pivotal ongoing study using Nilotinib for treatment of Parkinson's Disease and Alzheimer's Disease, helped start the first ever Parkinsonism and Dementia clinic, and participated in baseline cognitive and neurologic assessments of retired NFL players for the NFL Players association. Dr. Lawler has published a variety of papers and posters on topics involving the use of Nilotinib in the treatment of Parkinson's Disease and Lewy Body Disease. Dr. Lawler is experienced in treating many different neurologic conditions but specializes in the diagnosis and treatment of Movement Disorders, offering a wide variety of treatment options beyond traditional medical management for Parkinson's Disease including programming and management of Deep Brain Stimulation and the Duopa LCIG infusion pump. Dr. Lawler also specializes in the diagnosis and treatment of a variety of Autonomic conditions, muscle dystonia and spasticity using Botulinum toxin injections, as well as all of the various types of Dementia. Dr. Lawler is very passionate about the care and treatment of patients with memory disorders and plans to start a new program and center of excellence with the goal of not only improving patient care and treatment options but starting a nationwide campaign of awareness.